<?xml version='1.0' encoding='utf-8'?>
<document id="24755134"><sentence text="Why did the FDA approve efavirenz 800 mg when co-administered with rifampin?"><entity charOffset="24-33" id="DDI-PubMed.24755134.s1.e0" text="efavirenz" /><entity charOffset="67-76" id="DDI-PubMed.24755134.s1.e1" text="rifampin?" /><pair ddi="false" e1="DDI-PubMed.24755134.s1.e0" e2="DDI-PubMed.24755134.s1.e0" /><pair ddi="false" e1="DDI-PubMed.24755134.s1.e0" e2="DDI-PubMed.24755134.s1.e1" /></sentence><sentence text="Literature reports regarding the efficacy of efavirenz (EFV) 600 mg with rifampin (RIF) are not consistent"><entity charOffset="45-54" id="DDI-PubMed.24755134.s2.e0" text="efavirenz" /><entity charOffset="73-81" id="DDI-PubMed.24755134.s2.e1" text="rifampin" /><entity charOffset="83-86" id="DDI-PubMed.24755134.s2.e2" text="RIF" /><pair ddi="false" e1="DDI-PubMed.24755134.s2.e0" e2="DDI-PubMed.24755134.s2.e0" /><pair ddi="false" e1="DDI-PubMed.24755134.s2.e0" e2="DDI-PubMed.24755134.s2.e1" /><pair ddi="false" e1="DDI-PubMed.24755134.s2.e0" e2="DDI-PubMed.24755134.s2.e2" /><pair ddi="false" e1="DDI-PubMed.24755134.s2.e1" e2="DDI-PubMed.24755134.s2.e1" /><pair ddi="false" e1="DDI-PubMed.24755134.s2.e1" e2="DDI-PubMed.24755134.s2.e2" /></sentence><sentence text=" Evaluation of a drug-drug interaction (DDI) study and supportive semi-mechanistic population pharmacokinetic (PK) analyses were undertaken to help delineate this issue" /><sentence text="" /><sentence text="DDI study and supportive semi-mechanistic population PK analyses were provided by BMS" /><sentence text=" Population PK analysis was based on six studies with intensive EFV PK sampling" /><sentence text=" An ACTG study with sparse PK sampling was used for model evaluation" /><sentence text=" Simulations compared EFV exposure at various doses in combination with RIF to EFV exposures at 600 mg once daily (QD)"><entity charOffset="72-74" id="DDI-PubMed.24755134.s8.e0" text="RIF" /></sentence><sentence text=" Effects of CYP2B6 genotypes on the magnitude of EFV-RIF interaction were also explored"><entity charOffset="53-55" id="DDI-PubMed.24755134.s9.e0" text="RIF" /></sentence><sentence text="" /><sentence text="In DDI study, co-administering EFV 600 mg QD and RIF reduced mean EFV exposure by ~ 30%"><entity charOffset="49-51" id="DDI-PubMed.24755134.s11.e0" text="RIF" /></sentence><sentence text=" Population PK model provided acceptable predictive performance of central tendency and variability for EFV C0, Cmax, and AUC" /><sentence text=" Simulations predicted that increasing EFV to 800 mg QD with RIF would result in EFV AUC and Cmax similar to EFV 600 mg QD alone"><entity charOffset="61-63" id="DDI-PubMed.24755134.s13.e0" text="RIF" /></sentence><sentence text=" EFV AUC and Cmax were ~ 2 times higher in subjects with reduced function CYP2B6 genotypes" /><sentence text=" However, the RIF effect was consistent across all genotypes"><entity charOffset="14-16" id="DDI-PubMed.24755134.s15.e0" text="RIF" /></sentence><sentence text=" EFV dose adjustment to 800 mg QD did not increase the risk of overexposure compared to 600 mg EFV QD within each genotype" /><sentence text="" /><sentence text="Dose adjustment based on matching systemic exposure was recommended to mitigate the potential for sub-therapeutic EFV exposures" /><sentence text=" Our review did not reveal any safety concerns in subjects receiving EFV 800 mg QD with RIF"><entity charOffset="88-90" id="DDI-PubMed.24755134.s19.e0" text="RIF" /></sentence><sentence text="" /></document>